EPCAM and neoplasm: We demonstrate a high level of specificity toward tumor cells overexpressing EpCAM and observe superior potency and specificity with the ETA translocation domain-based construct compared with the DT translocation domain-based construct previously explored for targeting RRSP to the natural DT receptor.